

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-129)	EMERFETAMAB
PRONUNCIATION	em" er fet' a mab
THERAPEUTIC CLAIM	Treatment of patients with acute myeloid leukemia (AML)

CHEMICAL NAMES

1. Immunoglobulin, anti-(human sialic acid-binding Ig-like lectin 3) (human monoclonal 1837MNGssmAbc single-chain variable fragment VH1-(GGGGS)3-VL1) fusion protein with peptide linker (GGGGS) fusion protein with immunoglobulin anti-(human CD3 antigen ϵ -chain) (human monoclonal 1837MNGssmAbc single-chain variable fragment VH2-(GGGGS)3-VL2) fusion protein with fusion protein with peptide linker (GGGG) fusion protein with immunoglobulin G1 (human γ 1-chain C-region C-terminal fragment) fusion protein with peptide linker (GGGGS)6 fusion protein with immunoglobulin G1 (human γ 1-chain C-region C-terminal fragment)
2. immunoglobulin scFv-scFv-scFc, anti-[*Homo sapiens* CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67)] and anti-[*Homo sapiens* CD3E (CD3 epsilon, Leu-4)], monoclonal antibody single chain (scFv)₂-scFc, bispecific; IG scFv-scFv-scFc single chain, anti-CD33 and anti-CD3E (1-993) [scFv-VH-V-kappa anti-CD33 (1-250) [VH (*Homo sapiens* IGHV1-18*01 G49>C (44) (81.6%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.15] (26-33.51-58.97-111) (1-122) -15-mer tris(tetraglycyl-seryl) linker (123-137) -V-KAPPA (*Homo sapiens* IGKV4-1*01 (83.2%) -IGKJ5*01 Q120>C (243) (91.7%)) CDR-IMGT [12.3.9] (164-175.193-195.232-240) (138-250)]-6-mer seryl-tetraglycyl-seryl linker (251-256) -scFv-VH-V-lambda anti-CD3E (257-505) [VH (*Mus musculus* IGHV10-1*02 (91.9%) -(IGHD) -IGHJ3*01 (86.7%)/*Homo sapiens* IGHV3-73*01 (87%) -(IGHD) -IGHJ5*01 (100%)) CDR-IMGT [8.10.16] (282-289.307-316.355-370) (257-381) -15-mer tris(tetraglycyl-seryl) linker (382-396) -V-LAMBDA (*Homo sapiens* IGLV7-43*01 (85.1%) -IGLJ3*02 (100%)) CDR-IMGT [9.3.9] (422-430.448-450.487-495) (397-505)] -4-mer tetraglycyl linker (506-509) -scFc (h-CH2-CH3)-(h-CH2-CH3) (510-993) [*Homo sapiens* IGHG1*03 h-CH2-CH3, nG1m1 (hinge 6-15 (510-519), CH2 R83>C (581), N84.4>G (586), V85>C (591) (520-629), CH3 E12 (645), M14 (647) (630-734), CHS (735-736)) (510-736) -30-mer hexakis(tetraglycyl-seryl) linker (737-766) -*Homo sapiens* IGHG1*03 h-CH2-CH3, nG1m1 (hinge 6-15 (767-776), CH2 R83>C (838), N84.4>G (843), V85>C (848) (777-886), CH3 E12 (902), M14 (904) (887-991), CHS (992-993)) (767-993)]], produced in Chinese hamster ovary (CHO) cells, non-glycosylated (Source: WHO pINN list 123)

STRUCTURAL FORMULA

Sequence

QVQLVQSGAE	VKKPGESVKV	SCKASGYTFT	NYGMNWKQA	PGQCLEWMGW	50
INTYTGEPTY	ADKFQGRVTM	TTDTSTSTAY	MEIRNLGGDD	TAVYYCARWS	100
WSDGYVYVFD	YWQGTSVTV	SSGGGSGGG	GSGGGSDIV	MTQSPDSLTV	150
SLGERTTINC	KSSQSVLDSS	TNKNLAWYQ	QKPGQPKLL	LSWASTRESG	200
IPDRFSGSGS	GTDFTLTIDS	PQPEDSATYY	CQSAHFPIIT	FGCGTRLEIK	250
SGGGGSEVQL	VESGGGLVQP	GGSLKLSCAA	SGFTFNKYAM	NWVRQAPGKG	300
LEWVARIRSK	YNNYATYYAD	SVKDRFTISR	DDSKNTAYLQ	MNNLKTEDTA	350
VYYCVRHGNF	GNSYISYWAY	WGQTLVTVS	SGGGSGGGG	SGGGGSQTVV	400
TQEPSLTVSP	GGVTTLTCGS	STGAVTSGNY	PNWVQKPGQ	APRGLIGGTK	450
FLAPGTPARF	SGLLGGKAA	LTLSGVQPED	EAEYCVLWY	SNRWFVGGGT	500
KLTVLGGGGD	KTHTCPPCPA	PELLGGPSVF	LFPPKPKDTL	MISRTPEVTC	550
VVVDVSHEDP	EVKFNWYVDG	VEVHNAKTKP	CEEQYGSTYR	CVSVLTVLHQ	600
DWLNGKEYKC	KVSNKALPAP	IEKTISKAKG	QPREPQVYTL	PPSREEMTKN	650
QVSLTCLVKG	FYPSDIAVEW	ESNGQPENNY	KTTTPVLDSD	GSFFLYSKLT	700
VDKSRWQQGN	VFSCVMHEA	LHNHYTQKSL	SLSPKGGGG	SGGGSGGGG	750
SGGGSGGGG	SGGGSDKTH	TCPPCPAPEL	LGGPSVFLFP	PKPKDTLMIS	800
RTPEVTCVVV	DVSHEDPEVK	FNWYVDGVEV	HNAKTKPCEE	QYGSTYRCVS	850
VLTVLHQDWL	NGKEYKCKVS	NKALPAPIEK	TISKAKQPR	EPQVYTLPPS	900
REEMTKNQVS	LTCLVKGFYP	SDIAVEWESN	GQPENNYKTT	PPVLDSDGSF	950
FLYSKLTVDK	SRWQQGNVFS	CSVMHEALHN	HYTQKSLSLS	PGK	993

Disulfide bridges

22-96	44-243	160-231	278-354	418-486	515-772	518-775	550-610
581-591	656-714	807-867	838-848	913-971			

MOLECULAR FORMULA $C_{4707}H_{7205}N_{1271}O_{1483}S_{39}$

MOLECULAR WEIGHT 106.5 kDa

TRADEMARK None as yet

SPONSOR Amgen

CODE DESIGNATIONS AMG 673

CAS REGISTRY NUMBER 2250261-27-7

UNII HOG226RYH1

WHO NUMBER 11239

gbk